A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

被引：0
|
作者：
Ismaila, Afisi S. [1 ,2 ]
Haeussler, Katrin [3 ]
Malmenas, Mia [4 ]
Sharma, Raj [5 ]
Compton, Chris [5 ]
Vogelmeier, Claus F. [6 ,7 ]
Han, MeiLan K. [8 ]
Halpin, David M. G. [9 ]
机构：
[1] GSK, Value Evidence & Outcomes, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[3] ICON Plc, ICON Hlth Econ, Munich, Germany
[4] ICON Plc, ICON Hlth Econ, Stockholm, Sweden
[5] GSK, Value Evidence & Outcomes, R&D Global Med, Brentford, England
[6] Philipps Univ Marburg, German Ctr Lung Res DZL, Dept Med Pulm & Crit Care Med, Marburg, Germany
[7] German Ctr Lung Res DZL, Marburg, Germany
[8] Univ Michigan, Div Pulm & Crit Care, Ann Arbor, MI USA
[9] Univ Exeter, Med Sch, Coll Med & Hlth, Exeter, England
来源：
ADVANCES IN THERAPY | 2023年 / 40卷 / 05期
关键词：
COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy; OBSTRUCTIVE PULMONARY-DISEASE; EFFICACY;
D O I：
10.1007/s12325-023-02495-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：2556 / 2561
页数：6
相关论文
共 50 条
  • [1] A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
    Afisi S. Ismaila
    Katrin Haeussler
    Mia Malmenäs
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2023, 40 : 2556 - 2561
  • [2] Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
    Jonathan Marshall
    Akanksha Sharma
    Patrick Darken
    Mario Ouwens
    Barinder Singh
    Deniz Tansey-Dwyer
    Advances in Therapy, 2023, 40 : 2549 - 2555
  • [3] Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"
    Marshall, Jonathan
    Sharma, Akanksha
    Darken, Patrick
    Ouwens, Mario
    Singh, Barinder
    Tansey-Dwyer, Deniz
    ADVANCES IN THERAPY, 2023, 40 (05) : 2549 - 2555
  • [4] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Afisi S. Ismaila
    Katrin Haeussler
    Alexandrosz Czira
    Ji-Hee Youn
    Mia Malmenäs
    Nancy A. Risebrough
    Jatin Agarwal
    Maria Nassim
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2022, 39 : 3957 - 3978
  • [5] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Ismaila, Afisi S.
    Haeussler, Katrin
    Czira, Alexandrosz
    Youn, Ji-Hee
    Malmenas, Mia
    Risebrough, Nancy A.
    Agarwal, Jatin
    Nassim, Maria
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2022, 39 (09) : 3957 - 3978
  • [6] Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [7] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [8] Network Meta-analysis (NMA) of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Compared with other Triple Therapies for the Treatment of chronic obstructive Pulmonary Disease (COPD): A Comparison of annualized Rates of moderate and severe Exacerbations
    Ismaila, A.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenaes, M.
    Risebrough, N.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C.
    Halpin, D.
    PNEUMOLOGIE, 2023, 77 : S96 - S96
  • [9] Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annual Moderate and Severe Exacerbations
    Ismaila, A. S.
    Haeussler, K.
    Czira, A.
    Youn, J.
    Malmenas, M.
    Risebrough, N.
    Agarwal, J.
    Nassim, M.
    Sharma, R.
    Compton, C.
    Vogelmeier, C. F.
    Halpin, D. M. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [10] Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects
    Allen, A.
    Henderson, A.
    Gupta, A.
    Renaux, J.
    Brealey, N.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
12345